To Evaluate Whether IVUS-guided Drug-eluting Stent (DES) Implantation Leads to Better Clinical Outcomes Compared to Conventional Angiography in the Treatment of Chronic Complete Occlusion (CTO) Disease.

• Primary coronary artery CTO lesion with visible collateral circulation
• Estimation of the time to complete occlusion (TIMI grade 0) ≥3 months based on clinical history and/or comparison with historical angiography or ECG
• It is suitable for target lesions of 2.25-4.0mm stent implantation
• The length of CTO lesion should be greater than 20mm
  • Clinical exclusion criteria:
• Pregnant and lactating women
• Severe coronary artery disease, not suitable for PCI
• Patients with acute myocardial infarction less than 7 days
• Long-term contraindications to DAPT (at least 1 year)
• Known renal insufficiency.20 mL/min / 1.73 ㎡)
• Left ventricular ejection fraction \<35% or cardiogenic shock
• The ICD implanted/CRT
• Severe bleeding or stroke within 6 months
• Have a history of allergy to iodine contrast agents or any known allergy to clopidogrel, ticagrelor, aspirin, or heparin
• Subjects have been diagnosed or suspected of liver disease, including laboratory evidence of hepatitis
• Valvular heart disease significantly affecting hemodynamics, hypertrophic cardiomyopathy, restrictive cardiomyopathy, or congenital heart disease
• Diseases that researchers believe may seriously harm patients, such as cancer and mental illness;Or the patient's life expectancy is less than one year and the follow-up cannot be completed;Or other conditions that researchers think might have confounded the results
• Participate in any other ongoing trial or intend to participate in another clinical trial of a drug or device within 12 months after baseline surgery
  • Angiographic exclusion criteria:
• The target lesion is located in the left main artery
• No visible collateral circulation in CTO lesions
• Target lesion is venous or arterial bypass graft
• The target vessel occlusion time (TIMI grade 0) \< 3 months can be determined

Criteria the registry did not label

• Clinical inclusion criteria:
• At least 18 years old
• Subjects will understand the test requirements, treatment and surgery, and can provide written informed consent
• Subjects with clinical symptoms of ischemic heart disease or evidence of myocardial ischemia associated with CTO target vessels and scheduled to undergo Percutaneous coronary intervention (PCI)
• Subjects will receive percutaneous coronary intervention
• Subjects are willing to accept all treatment and follow-up evaluations required by the protocol